HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Refractive status and optical components of premature babies with or without retinopathy of prematurity at 3-4 years old.

AbstractPURPOSE:
To investigate the refractive status and optical components of premature babies with or without retinopathy of prematurity (ROP) at 3-4 years old, and to explore the influence of prematurity and ROP on the refractive status and optical components.
METHODS:
Premature babies receiving fundus examination were recruited into ROP group and non-ROP group, with age-matched full-term babies as controls.
RESULTS:
The incidence of myopia was the highest in ROP (3/59, 5.08%). The incidence of astigmatism was significantly different between ROP (37.29%, 22/59) and controls (17.86%, 15/84). The corneal refractive power in ROP and non-ROP was more potent compared with controls (P<0.05); corneal curvature was steeper (P<0.05); lens thickness was thinner (P<0.05); ocular axial length was shorter P<0.05). The gestational age was negatively related to corneal astigmatism and astigmatism, positively associated with vitreous thickness and axial length. The birth-weight was negatively associated with corneal astigmatism, astigmatism and corneal refractive power, positively related to corneal radius of curvature, vitreous thickness and ocular axial length.
CONCLUSION:
Premature babies with or without ROP are susceptible to myopia and astigmatism. ROP, prematurity and low birth-weight synergistically influence the development of refractive status and optical components, of which the prematurity and low birth-weight are more important.
AuthorsLi-Juan Ouyang, Zheng-Qin Yin, Ning Ke, Xin-Ke Chen, Qin Liu, Jing Fang, Lin Chen, Xiu-Rong Chen, Hui Shi, Ling Tang, Lian-Hong Pi
JournalInternational journal of clinical and experimental medicine (Int J Clin Exp Med) Vol. 8 Issue 7 Pg. 11854-61 ( 2015) ISSN: 1940-5901 [Print] United States
PMID26380027 (Publication Type: Journal Article)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: